Case Report {#S1}
===========

Patient A, a 5-day-old infant female, 2.2 kg, born prematurely at 35 weeks gestational age, was transported to an outside hospital emergency room *via* emergency medical services following an apneic event at home that resolved after the administration of a few rescue breaths by the mother. Upon presentation to the emergency room, the patient demonstrated stable vital signs and was subsequently transferred to our pediatric intensive care unit (PICU) for respiratory monitoring and diagnostic workup for the cause of the apneic event. Upon arrival to the PICU, the patient was vigorous, crying, and tachypneic, but, otherwise, with relatively normal vitals signs (HR 145, BP 77/44, 97% on 1 LPM NC O2). Given the patient's age and history of apnea, a workup to rule out serious bacterial infection was initiated. Basic labs were sent, and a lumbar puncture was completed showing 20 WBC/μL (2,030 RBC/μL) with 33% neutrophils. Broad-spectrum antimicrobials were initiated including ceftriaxone (50 mg/kg/dose prior to arrival to PICU), acyclovir (60 mg/kg/day), and ampicillin (400 mg/kg/day). Initial labs were significant for thrombocytopenia (platelets 39,000/μL) but without any other cytopenias (Hgb 17.1 g/dL, WBC 8,760/μL).

At hour 6 after admission, the patient rapidly decompensated and developed lethargy, respiratory failure due to apnea, and was intubated and mechanically ventilated. At hour 10 after admission, additional laboratory testing revealed very elevated liver transaminases (ALT 2,214, AST \> 7,500), severe coagulopathy (PT \> 120, INR \> 16.6, PTT \> 200) and a ferritin of 241,000 ng/mL (result verified with duplication). The patient's triglyceride level was 41 mg/dL, and serum lactate level at this time was significantly elevated at 14 mmol/L.

At hour 18 after admission, the HSV PCR from CSF returned positive for HSV-2, and the C-reactive protein (CRP) was elevated (2.09 mg/dL). We made the preliminary diagnosis of HSV-associated hemophagocytic lymphohistiocytosis (HLH) based on a similar case report ([@B1]). The patient's respiratory and hemodynamic profile continued to deteriorate (Figure [1](#F1){ref-type="fig"}A) in spite of escalating vasopressor support (Figure [1](#F1){ref-type="fig"}B), and the patient needed repeated fluid boluses of colloid (5% human serum albumin in NS) and blood product administration (Figure [1](#F1){ref-type="fig"}C) to maintain mean arterial pressure (MAP) of at least 40 mmHg. At this time, 30 mg/kg methylprednisolone was administered to ameliorate the inflammatory process and, with the addition of norepinephrine, the patient stabilized transiently, and we were able to wean the epinephrine support slightly (Figure [1](#F1){ref-type="fig"}B).

![**Vasopressor and fluid resuscitation support needed to maintain a minimum mean arterial pressure (MAP) of 40 mmHg**. The kinetics of the mean arterial blood pressure as determined by non-invasive blood pressure (NIBP) "cuff" (blue line) and continuous invasive blood pressure (CIBP) "arterial line" (red line) **(A)**. The dosing of vasopressors, expressed as vasopressor potency, against time **(B)**. Given their higher biologic activity, vasopressor potency for epinephrine (red line) and norepinephrine (green line) were calculated as the dose (μg/kg/min) × 100, whereas the vasopressor potency of dobutamine (blue line) was calculated as simply the dose of dobutamine (microgram per kilogram per minute). Ongoing fluid resuscitation using both colloid (5% albumin in NS) and blood products (including packed red blood cells and fresh frozen plasma) needed to maintain a minimum MAP of 40 mmHg (dotted line) **(C)**.](fped-04-00077-g001){#F1}

At hour 30 after admission, the patient again became unstable and required repeated volume resuscitation in the form of colloid fluid boluses to maintain the MAP goal of 40 mmHg, and then, even this MAP goal became unobtainable. After long discussion with the parents, it was decided that recovery was unlikely and technological support was withdrawn. The parents agreed to an autopsy, and the report stated that "the presence of hemophagocytosis was demonstrated with the bone marrow and spleen exhibiting large cells containing particles consistent with ingested, disintegrating blood cells. Given that diagnostic guidelines for HLH designate bone marrow, lymph node, and spleen as the organs, which most reliably show the histologic features, and secondary HLH can be triggered by systemic infection, as this patient had, the findings post-mortem supported a diagnosis of HLH."

Discussion {#S2}
==========

We find this case to be of interest given the rapid deterioration of a patient with HSV-associated multiple organ dysfunction syndrome (MODS). Unfortunately, delivery of anti-inflammatory treatment did not significantly affect the outcome. Historically, the patient would have been diagnosed with neonatal HSV-associated fulminant hepatitis ([@B2], [@B3]). However, the patient also had a very elevated ferritin level of 241,000 ng/mL. This led us to preliminarily diagnose the patient with HSV-associated HLH ([@B4]). Of the eight criteria proposed in the HLH-2004 guidelines ([@B5]), our patient met four out of the five requisite criteria for a diagnosis of HLH: Temperature instability (Patient's T~min~ 35.9°C)Hypofibrinogenemia (Patient's fibrinogen = 94 mg/dL)Hyperferritinemia (Patient's ferritin = 241,000 ng/mL)Cytopenias (affecting ≥2 out of 3 lineages in the peripheral blood)Platelets \<100 × 10^9^/L (Patient's Plts = 38 × 10^9^/L)Hemoglobin \<9 g/dL in infants \<4 weeks of age (Patient's Hgb = 8.1 g/dL).

It is notable that the patient did not have anemia when she was first admitted. However, her hemoglobin fell precipitously and was maintained at approximately 10 g/dL with packed red blood cell (pRBC) transfusions to maintain oxygen carrying capacity in light of an ongoing lactic acidosis. The soluble interleukin (IL)-2 receptor (sCD25) was sent 28 h after admission and showed a value of 755 pg/mL (85.3 U/mL), far less than the 2,400 U/mL cut-point defined by HLH-2004 diagnostic criteria. Natural killer (NK)-cell activity was not performed though it would be expected to be low ([@B6]). Furthermore, hemophagocytosis was seen on autopsy. Therefore, if one includes the hemophagocytosis seen on autopsy, this patient met HLH criteria, and the high dose pulse of methylprednisolone seems to have been appropriate. Interestingly, following the high dose pulse of methylprednisolone (30 mg/kg), the ferritin fell to 33,600 ng/mL and the CRP to 0.89 mg/dL at 38-h post-admission.

In terms of risk factors for familial HLH, the parents were neither related nor were family histories of early unexpected death obtained. While not frequently described, case reports reveal that hyperferritinemia may be present in disseminated neonatal HSV infection. Yamada et al. described a 4-day-old male infant with HSV-I infection and a ferritin of \>15,000 ng/mL, who seemed to respond to methylprednisolone (30 mg/kg/day), intravenous immunoglobulin (IVIG, 1 g/kg/day), and whole blood exchange transfusion, who recovered completely ([@B1]). Imashuku et al. described three neonatal patients (age 3--14 days), who they described as fulfilling diagnostic criteria for HLH, who also had HSV infection, and who all died as a result of MODS ([@B4]). Vladescu et al. recently described three neonatal patients (age 6--10 days) with HSV infection and hyperferritinemia (\>40,000--68,090) ([@B7]). Of these three patients, the only patient to survive was the patient who fulfilled 6 out of 8 criteria for HLH but was not started on HLH-2004 therapy due to her improving condition on acyclovir alone ([@B7]).

These cases invite speculation that hyperferritinemia may be a feature of disseminated HSV infection. So, what is the reason for the hyperferritinemia during HSV infection and for that matter, HLH/macrophage activation syndrome (MAS)? Ferritin is a key molecule that serves to limit pro-oxidant stress that typifies inflammatory conditions ([@B8]), and the major source of serum ferritin is tissue macrophages ([@B9]). Interestingly, pediatric patients with ferritin levels greater than 3,000 ng/mL have an increased risk of death ([@B10]). While the details are unclear, ferritin expression by macrophages is induced by pro-inflammatory cytokines including IL-1, IL-6, IL-12, IL-18, interferon-gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) ([@B11]). Of course, from a pediatric intensivist's perspective, while the cause of the cytokine storm is important, stopping it is essential.

Various strategies and therapeutic regimens have been applied to HLH and MAS. In 1994, the Histiocyte Society published a protocol with the recommendation of an etoposide and dexamethasone-based regimen, which remains the basis of initial therapy for HLH, with definitive therapy being hematopoietic cell transplantation (HCT) ([@B12]). For genetic deficiency-verified familial HLH, this approach seems very reasonable. However, at the present, genetic verification takes weeks, and the administration of cytotoxic agents to patients with fulminant shock is potentially risky. In our case, the hematology/oncology team was comfortable with high dose steroids but wanted further lab results prior to committing to the etoposide-based regimen. However, etoposide may have a role in the acute setting of shock and MAS/HLH as a preclinical mouse model has shown that it selectively depletes activated T lymphocytes ([@B13]). To the authors' knowledge, the safety of etoposide administration in a patient with fulminant shock has not been studied. Another immuno-modulatory approach, therapeutic plasma exchange (TPE) coupled with IVIG and methylprednisolone, has been used clinically ([@B14]). Given the patients' small size (2.2 kg), placement of an apheresis catheter was not attempted and, therefore, TPE was not performed. IVIG administration was considered and ordered, but the decision to withdrawal of technological support was made before it could be administered.

The hyperferritinemia of MAS/HLH most likely represents a hypercytokinemic storm, and the targeting of the component cytokines, including IL-1, IL-6, and IFNγ, is becoming a target of active research ([@B15]). In fact, anakina (Kineret), an IL-1 receptor antagonist, has been used successfully in similar cases of secondary HLH/MAS/MODS ([@B16]). In our case, anakinra was not on formulary and was unavailable. Ultimately, increased specificity and expedited delivery of the diagnosis will be vital to answer the question as to the most appropriate therapy. Indeed, much of the historical discussion in the literature up to this point regarding HLH, MAS, and hyperferritinemic sepsis-related MODS has revolved around making the distinction of familial versus secondary HLH, and the difference in treatment between the two. However, may be it is time to change the paradigm of the discussion and, instead, generate a more inclusive criterion that would speed diagnosis and treatment of the cytokine storm first, with later determination of the cause of the storm. Such a broadened criterion may be hyperferritinemic sepsis (HFS), with or without MODS. The broadened HFS criterion may expedite diagnosis as it would decrease the initial number of hard to obtain laboratory values, and, instead, the preliminary criteria would be based on clinical findings and an elevated ferritin value alone. It would also help clinical research, as the criteria for HLH are strict. The simplified criteria for HFS may increase the number of patients who would meet eligibility criteria for initial anti-inflammatory therapy. While increasing sensitivity, the use of HFS criterion would decrease diagnostic specificity of HLH. However, a tiered approach to treatment could be undertaken, allowing for earlier therapy initiation while diagnostic testing is pending. Absence or presence of MODS would impact the risk benefit ratio and treatment decisions regarding more aggressive therapies including cytokine blockade ([@B16]) or TPE ([@B17]), and subsequent results of genetic testing would dictate the later decisions about HSCT. We are not sure, regardless of treatment, if this patient could have survived, but we hope that these patients can be captured for future research on hyperferritinemic sepsis.
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